UniQure BV of the Netherlands has announced the appointment of Hans Christian Rohde as its chief commercial officer to lead the roll-out of Glybera, the western world’s first approved gene therapy. Mr Rohde joins UniQure from Basilea Pharmaceutica Ltd in Switzerland where he was chief commercial officer and a member of the company’s executive management committee. Prior to this, he was head of reproductive health and endocrinology at Merck-Serono (Merck KGaA) and before that, head of international marketing at Biogen Idec.
Glybera was approved in Europe in November 2012 for the treatment of patients with lipoprotein lipase deficiency.
UniQure announced the appointment on 6 December 2012.
Copyright 2012 Evernow Publishing Ltd.